Iridex Corp cash flow statement IRIX

Annual Quarterly

In Q2 of fiscal 2026, the quarter ended Jul 4, 2026, Iridex Corp generated $174,000 of cash from operations, up 143.8% from the same quarter a year earlier. It spent $50,000 on capital expenditures. That left free cash flow of $124,000.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Jul 4, 2026	Q2 FY2026 Jul 4, 2026	Q1 FY2026 Apr 4, 2026	Q3 FY2025 Sep 27, 2025	Q2 FY2025 Jun 28, 2025	Q1 FY2025 Mar 29, 2025	Q4 FY2024 Dec 28, 2024	Q3 FY2024 Sep 28, 2024	Q2 FY2024 Jun 29, 2024
Operating
Depreciation and amortization	—	0 -32.3%	0 -25.9%	0 -19.7%	0 -8.6%	0 -22.0%	0 -78.2%	0 +30.5%	0 -39.6%
Operating cash flow	—	0 +143.8%	-1 -16.2%	-1 +62.3%	-0 +70.1%	-1 +30.3%	-1 -26.5%	-3 -72.4%	-1 -16.2%
Investing
Capital expenditures	—	0 +284.6%	0 +818.2%	0 +1200.0%	0	0 +266.7%	0 -71.9%	0 -98.8%	0 -100.0%
Investing cash flow	—	-0 -284.6%	-0 -818.2%	-0 -1200.0%	-0	-0 -266.7%	-0 -128.1%	-0 +98.8%	0 +100.0%
Financing
Financing cash flow	—	-0 -171.4%	-0 -100.0%	-0 -101.2%	-0	6	-0 -584.4%	3 +11862.5%	0 +100.0%
Change in cash
Net change in cash	—	0 +118.2%	-1 -129.5%	-1 -380.1%	-0 +64.4%	5 +400.7%	-1 -55.5%	-0 +86.4%	-1 -6.6%
Free cash flow	—	0 +130.2%	-1 -23.8%	-1 +61.9%	-0 +69.1%	-1 +29.7%	-1 -23.3%	-3 -64.9%	-1 -14.6%
Per share
Free cash flow per share	—	0.01 +129.2%	-0.08 -19.6%	-0.07 +62.9%	-0.02 +70.0%	-0.07 +31.7%	-0.07 -20.5%	-0.19 -61.4%	-0.08 -12.8%
Ratios
Free cash flow margin	—	0.99%	-12.17%	-9.38%	-3.02%	-9.75%	-9.82%	-26.54%	-10.50%
Capital expenditures to revenue	—	0.40%	0.86%	0.10%	0.10%	0.09%	0.07%	0.01%	0.00%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry: Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as: IRIX (Nasdaq)
Fiscal year ends: January 3
Incorporated in: DE
Headquarters: Mountain View, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1006045

Other Electromedical & Electrotherapeutic Apparatus companies

All 31 Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.